Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEMETER: Double vs Standard Empagliflozin Dose for Metabolic Syndrome
NCT05905965Phase 3Recruiting
- Sponsor
- Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin in metabolic syndrome (2 arms), sponsored by Collegium Medicum of Nicolaus Copernicus University in Bydgoszcz. Primary endpoints: Body Mass Index at 6 months and Glycated Hemoglobin at 6 months. Started May 2023; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT05905965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905965.